Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Martin Krsak

TitleAssociate Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
ORCID ORCID Icon0000-0002-1746-7462 Additional info

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Cortes-Penfield N, Krsak M, Damioli L, Henry M, Seidelman J, Hewlett A, Certain L. How We Approach Suppressive Antibiotic Therapy Following Debridement, Antibiotics, and Implant Retention for Prosthetic Joint Infection. Clin Infect Dis. 2024 01 25; 78(1):188-198. PMID: 37590953.
      View in: PubMed
    2. Texidor WM, Miller MA, Molina KC, Krsak M, Calvert B, Hart C, Storer M, Fish DN. Oritavancin as sequential therapy for Gram-positive bloodstream infections. BMC Infect Dis. 2024 Jan 24; 24(1):127. PMID: 38267844.
      View in: PubMed
    3. Krsak M, Scherger S, Miller MA, Cobb V, Montague BT, Henao-Mart?nez AF, Molina KC. Substance use disorder-associated infections' treatment with dalbavancin enabling outpatient transition (SUDDEN OUT) - an investigator-initiated single-arm unblinded prospective cohort study. Ther Adv Infect Dis. 2024 Jan-Dec; 11:20499361231223889. PMID: 38249543.
      View in: PubMed
    4. Laper S, Hileman CO, Block G, Erlandson KM, Krsak M. Perceived Risks and Benefits and Frequency of Cannabis Use Among People with HIV in Different Legal Environments. AIDS Res Hum Retroviruses. 2024 05; 40(5):293-300. PMID: 37823750.
      View in: PubMed
    5. Mueller SW, Blass B, Molina KC, Gibson C, Krsak M, Kohler AD, Deeter L, Stalilonis J, Wiktor AJ. Augmented Renal Function in Burn Patients: Occurrence and Discordance With Commonly Used Methods to Assess Renal Function. J Burn Care Res. 2023 11 02; 44(6):1298-1303. PMID: 37450897.
      View in: PubMed
    6. Coyle DT, Stewart S, Bortz C, Manalo J, Ritvo A, Krsak M. Buprenorphine Prescribing and Dosing Limits: Evidence and Policy Goals. Subst Abus. 2023 Jan-Apr; 44(1):17-23. PMID: 37226901.
      View in: PubMed
    7. Molina KC, Mueller SW, Miller MA, Krsak M. Response to Mahatanan and Kang: It's Complicated. Open Forum Infect Dis. 2023 May; 10(5):ofad210. PMID: 37180593.
      View in: PubMed
    8. Tamma PD, Komarow L, Ge L, Garcia-Diaz J, Herc ES, Doi Y, Arias CA, Albin O, Saade E, Miller LG, Jacob JT, Satlin MJ, Krsak M, Huskins WC, Dhar S, Shelburne SA, Hill C, Baum KR, Bhojani M, Greenwood-Quaintance KE, Schmidt-Malan SM, Patel R, Evans SR, Chambers HF, Fowler VG, van Duin D. Clinical Impact of Ceftriaxone Resistance in Escherichia coli Bloodstream Infections: A Multicenter Prospective Cohort Study. Open Forum Infect Dis. 2022 Nov; 9(11):ofac572. PMID: 36381622.
      View in: PubMed
    9. Molina KC, Lunowa C, Lebin M, Segerstrom Nunez A, Azimi SF, Krsak M, Mueller SW, Miller MA. Comparison of Sequential Dalbavancin With Standard-of-Care Treatment for Staphylococcus aureus Bloodstream Infections. Open Forum Infect Dis. 2022 Jul; 9(7):ofac335. PMID: 35899276.
      View in: PubMed
    10. Morrisette T, Molina KC, Da Silva B, Mueller SW, Damioli L, Krsak M, Miller MA, Fish DN. Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success. Open Forum Infect Dis. 2022 Jun; 9(6):ofac028. PMID: 35615295.
      View in: PubMed
    11. Hoover RK, Krsak M, Molina KC, Shah K, Redell M. Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties. Open Forum Infect Dis. 2022 May; 9(5):ofac090. PMID: 35392455.
      View in: PubMed
    12. Novak AR, Krsak M, Kiser TH, Neumann RT, Cava Prado L, Molina KC, Mueller SW. Pharmacokinetic Evaluation of Cefazolin in the Cerebrospinal Fluid of Critically Ill Patients. Open Forum Infect Dis. 2022 Feb; 9(2):ofab649. PMID: 35111872.
      View in: PubMed
    13. Molina KC, Miller MA, Mueller SW, Van Matre ET, Krsak M, Kiser TH. Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin. Clin Pharmacokinet. 2022 03; 61(3):363-374. PMID: 34931283.
      View in: PubMed
    14. Krsak M, Harry BL, Palmer BE, Franco-Paredes C. Response to Mishra et al. re "Postinfectious Immunity After COVID-19 and Vaccination Against SARS-CoV-2". Viral Immunol. 2021 11; 34(9):659-660. PMID: 34672802.
      View in: PubMed
    15. Rosolanka R, Henao-Martinez AF, Pisney L, Franco-Paredes C, Krsak M. COVID-19: a review of current knowledge regarding exposure, quarantine, isolation and other preventive measures. Ther Adv Infect Dis. 2021 Jan-Dec; 8:20499361211032039. PMID: 34349986.
      View in: PubMed
    16. Krsak M, Harry BL, Palmer BE, Franco-Paredes C. Postinfectious Immunity After COVID-19 and Vaccination Against SARS-CoV-2. Viral Immunol. 2021 10; 34(8):504-509. PMID: 34227891.
      View in: PubMed
    17. Mueller SW, Kedzior SK, Miller MA, Reynolds PM, Kiser TH, Krsak M, Molina KC. An overview of current and emerging antifungal pharmacotherapy for invasive fungal infections. Expert Opin Pharmacother. 2021 Jul; 22(10):1355-1371. PMID: 33878996.
      View in: PubMed
    18. Krsak M, Wada NI, Plankey MW, Kinney GL, Epeldegui M, Okafor CN, Friedman MR, Palella FJ, Erlandson KM. Self-Reported Cannabis Use and Markers of Inflammation in Men Who Have Sex With Men With and Without HIV. Cannabis Cannabinoid Res. 2021 04; 6(2):165-173. PMID: 33912681.
      View in: PubMed
    19. Quan NG, Latif H, Krsak M, Corbisiero MF, Solis J, Wand T, Mortaji P, Vrolijk MA, Kon S, Ghandnoosh N, Franco-Paredes C. Benefits of COVID-19 viral screening of formerly incarcerated individuals during community reentry. Ther Adv Infect Dis. 2021 Jan-Dec; 8:2049936120985951. PMID: 33505680.
      View in: PubMed
    20. Krsak M, Henao-Mart?nez AF, Franco-Paredes C. COVID-19: Way Forward With Serosurveillance Without Overemphasizing Neutralizing Antibodies. Viral Immunol. 2021 04; 34(3):130-133. PMID: 33181055.
      View in: PubMed
    21. Franco-Paredes C, Ghandnoosh N, Latif H, Krsak M, Henao-Martinez AF, Robins M, Vargas Barahona L, Poeschla EM. Decarceration and community re-entry in the COVID-19 era. Lancet Infect Dis. 2021 01; 21(1):e11-e16. PMID: 33007225.
      View in: PubMed
    22. Krsak M, Montague BT, Trowbridge P, Johnson SC, Binswanger IA. Opioid Use and Chronic Infections: The Value of Addressing the Syndemic in Correctional Settings Via Telemedicine Guidance and Broader Use of Long-Acting Medications. J Infect Dis. 2020 09 02; 222(Suppl 5):S486-S493. PMID: 32877543.
      View in: PubMed
    23. Franco-Paredes C, Jankousky K, Schultz J, Bernfeld J, Cullen K, Quan NG, Kon S, Hotez P, Henao-Mart?nez AF, Krsak M. COVID-19 in jails and prisons: A neglected infection in a marginalized population. PLoS Negl Trop Dis. 2020 06; 14(6):e0008409. PMID: 32569274.
      View in: PubMed
    24. Canfield GS, Schultz JS, Windham S, Scherger S, Henao-Martinez AF, Shapiro L, Franco-Paredes C, Chastain DB, Wand T, Krsak M. Empiric Therapies for COVID-19: Destined to Fail by Ignoring the Lessons of History. J Hosp Med. 2020 07 01; 15(7):434-436. PMID: 32584243.
      View in: PubMed
    25. Krsak M, Johnson SC, Poeschla EM. COVID-19 Serosurveillance May Facilitate Return-to-Work Decisions. Am J Trop Med Hyg. 2020 06; 102(6):1189-1190. PMID: 32329432.
      View in: PubMed
    26. Krsak M, Henao-Mart?nez AF, Franco-Paredes C. Screening for Covid-19 in Skilled Nursing Facilities. N Engl J Med. 2020 07 09; 383(2):190-191. PMID: 32469480.
      View in: PubMed
    27. Solis J, Franco-Paredes C, Henao-Mart?nez AF, Krsak M, Zimmer SM. Structural Vulnerability in the U.S. Revealed in Three Waves of COVID-19. Am J Trop Med Hyg. 2020 07; 103(1):25-27. PMID: 32383432.
      View in: PubMed
    28. Krsak M, Morrisette T, Miller M, Molina K, Huang M, Damioli L, Pisney L, Wong M, Poeschla E. Advantages of Outpatient Treatment with Long-Acting Lipoglycopeptides for Serious Gram-Positive Infections: A Review. Pharmacotherapy. 2020 05; 40(5):469-478. PMID: 32239771.
      View in: PubMed
    29. Krsak M, Damioli L. Is 2 Weeks of Treatment Enough for Cortical Bone Osteomyelitis? Clin Infect Dis. 2020 01 01; 70(1):179. PMID: 31069382.
      View in: PubMed
    30. Krsak M, Jeffers A, Shah J, Johnson SC, Montague BT. Access to Specialty Services: Opportunities for Expansion of Telemedicine to Support Correctional Health Care in Colorado. Telemed J E Health. 2020 06; 26(6):776-783. PMID: 31486710.
      View in: PubMed
    31. Morrisette T, Miller MA, Montague BT, Barber GR, McQueen RB, Krsak M. On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections. J Antimicrob Chemother. 2019 08 01; 74(8):2405-2416. PMID: 31322694.
      View in: PubMed
    32. Morrisette T, Miller MA, Montague BT, Barber GR, McQueen RB, Krsak M. Long-Acting Lipoglycopeptides: "Lineless Antibiotics" for Serious Infections in Persons Who Use Drugs. Open Forum Infect Dis. 2019 Jul; 6(7):ofz274. PMID: 31281868.
      View in: PubMed
    33. Krsak M, Patel NU, Poeschla EM. Case Report: Hepatic Fascioliasis in a Young Afghani Woman with Severe Wheezing, High-Grade Peripheral Eosinophilia, and Liver Lesions: A Brief Literature Review. Am J Trop Med Hyg. 2019 03; 100(3):588-590. PMID: 30628571.
      View in: PubMed
    34. Krsak M, Kent DM, Terrin N, Holcroft C, Skinner SC, Wanke C. Myocardial Infarction, Stroke, and Mortality in cART-Treated HIV Patients on Statins. AIDS Patient Care STDS. 2015 Jun; 29(6):307-13. PMID: 25855882.
      View in: PubMed
    Krsak's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (130) concept(s)
    _
    Co-Authors Expand Description
    See all (22) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)